Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know.
Authors: Bogers Sophie Helen
Journal: Frontiers in veterinary science
Summary
# Cell-Based Therapies for Joint Disease: Evidence Quality and Regulatory Gaps Autologous-conditioned serum, platelet-rich plasma, and mesenchymal stem cell products have become increasingly prevalent in equine joint disease management, yet their clinical utility remains poorly standardised across the industry. This narrative review examined the mechanisms, efficacy and processing variables of cell-based therapies in veterinary orthopaedics, revealing substantial inconsistencies in reported outcomes between studies and products. Critical factors driving this variation include preparation methodology, cell source (adipose vs. bone marrow), disease stage at treatment (early vs. late-stage osteoarthritis), and presence of concurrent soft tissue injury—variations that undermine direct clinical comparisons and evidence synthesis. Despite widespread use, these biologics meet regulatory definitions as drugs but operate largely outside established safety and efficacy frameworks; the review outlines FDA guidelines as a potential pathway for demonstrating manufacturing consistency and clinical effectiveness. For equine professionals, this work highlights the necessity of critically evaluating the evidence base underpinning commercial products and emphasises that treatment decisions should account for case-specific factors and product-specific validation rather than assuming equivalence across different cell-based formulations or preparation techniques.
Read the full abstract on PubMed
Practical Takeaways
- •Cell-based therapy products vary widely in composition and effectiveness — understand the specific preparation method and source material (adipose, bone marrow, or whole blood derived) of any product you consider using
- •Treatment outcomes depend heavily on case selection (disease stage and type of injury); early-stage OA or soft tissue injuries may respond differently than advanced joint disease
- •Until regulatory standards are established, critically evaluate the evidence quality and manufacturing consistency of any cell-based therapy product before clinical application
Key Findings
- •Cell-based therapies (autologous-conditioned serum, platelet-rich plasma, mesenchymal stem cells) show significant variation in efficacy outcomes in canine and equine patients due to differences in preparation technique and cell source
- •Study design factors including disease stage (early vs. late OA) and injury type substantially influence reported treatment outcomes
- •Current cell-based therapies for OA meet FDA drug definitions but operate in under-regulated field with concerns for product safety, consistency, and efficacy
- •Standardization of production methods and research protocols is essential to establish clinical validity and meet regulatory approval requirements